Skip to main content
Premium Trial:

Request an Annual Quote

Joseph Jimenez

uBiome has appointed Joseph Jimenez to its board of directors to support the firm's new drug discovery and development efforts. Prior to uBiome, Jimenez served as CEO of Novartis, where he focused on leading global businesses while divesting non-core divisions. Jimenez has a track record of business leadership at several companies, including Clorox, ConAgra, and H.J Heiz. In addition to uBiome's board of directors, Jimenez also serves on the boards of Procter & Gamble and General Motors. In addition, he served on the board of directors at Colgate-Palmolive from 2009 to 2015, and at AstraZeneca from 2002 to 2017.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.